Cassava Sciences (SAVA) News Today $2.55 -0.11 (-4.14%) (As of 12/17/2024 05:56 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVADecember 17 at 10:52 PM | globenewswire.comCASSAVA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc and Encourages Investors to Contact the FirmDecember 17 at 9:00 PM | globenewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVADecember 17 at 8:21 PM | globenewswire.comSAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitDecember 17 at 4:00 PM | prnewswire.comLevi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SAVADecember 17 at 5:45 AM | prnewswire.comInvestor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Cassava Sciences, Inc.December 16 at 8:47 PM | prnewswire.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. (SAVA)December 16 at 4:22 PM | globenewswire.comCassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVADecember 16 at 2:55 PM | globenewswire.comClass Action Filed Against Cassava Sciences, Inc. ...December 16 at 6:06 AM | gurufocus.comClass Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law FirmDecember 16 at 5:45 AM | prnewswire.comCASSAVA SCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVADecember 15 at 7:55 PM | businesswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVADecember 15 at 11:12 AM | investing.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. ...December 14, 2024 | gurufocus.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVADecember 14, 2024 | globenewswire.comROSEN, NATIONAL TRIAL LAWYERS, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SAVADecember 14, 2024 | investing.comSAVA Investors with Losses in Excess of $100K Have Opportunity to Lead Cassava Sciences, Inc. ...December 13, 2024 | gurufocus.comSAVA Investors with Losses in Excess of $100K Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud LawsuitDecember 13, 2024 | prnewswire.comSAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. ...December 13, 2024 | gurufocus.comSAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitDecember 13, 2024 | globenewswire.comRosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their RightsDecember 13, 2024 | businesswire.comSHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Cassava Sciences, Inc. (SAVA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmDecember 13, 2024 | globenewswire.comTidal Investments LLC Buys Shares of 375,000 Cassava Sciences, Inc. (NASDAQ:SAVA)Tidal Investments LLC bought a new stake in Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 375,000 shares of the company's stock, valued at approximatelyDecember 13, 2024 | marketbeat.comJames William Kupiec Sells 4,000 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) StockDecember 4, 2024 | insidertrades.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVADecember 3, 2024 | prnewswire.comLevi & Korsinsky Reminds Shareholders of an Investigation into Cassava Sciences, Inc. (SAVA) Regarding Potential Securities Fraud AllegationsDecember 3, 2024 | markets.businessinsider.comCassava Sciences: REFOCUS Unlikely To Save Simufilam, Careful Development NeededDecember 2, 2024 | seekingalpha.comCassava Sciences Faces Reality After Simufilam's Phase 3 FailureNovember 28, 2024 | seekingalpha.comFY2024 EPS Forecast for Cassava Sciences Reduced by AnalystCassava Sciences, Inc. (NASDAQ:SAVA - Free Report) - Investment analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Cassava Sciences in a report issued on Tuesday, November 26th. HC Wainwright analyst V. Bernardino now expects that the company will earnNovember 28, 2024 | marketbeat.comATTENTION SAVA SHAREHOLDERS: Investors who Lost Money on Cassava Sciences, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing InvestigationNovember 28, 2024 | markets.businessinsider.comA Post-Mortem on Cassava SciencesNovember 27, 2024 | finance.yahoo.comCassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flopsNovember 26, 2024 | msn.comCassava Sciences downgraded to Neutral from Buy at H.C. WainwrightNovember 26, 2024 | markets.businessinsider.comCassava Sciences (NASDAQ:SAVA) Downgraded to Neutral Rating by HC WainwrightHC Wainwright lowered Cassava Sciences from a "buy" rating to a "neutral" rating in a report on Tuesday.November 26, 2024 | marketbeat.comCassava Sciences stock plummets after Phase III Alzheimer’s failNovember 25, 2024 | finance.yahoo.comCassava announces Phase 3 ReThink-ALZ data did not meet co-primary endpointsNovember 25, 2024 | markets.businessinsider.comCassava Sciences Plummets 84% After Embattled Alzheimer's Drug FlopsNovember 25, 2024 | msn.comCassava Sciences sinks 84% to $4.21 after Alzheimer’s study missNovember 25, 2024 | markets.businessinsider.comCassava Sciences' Alzheimer's Treatment Didn't Meet Endpoints in Study; Shares Dive -- UpdateNovember 25, 2024 | marketwatch.comCassava Sciences' stock on track for biggest-ever selloff after failed Alzheimer's trialNovember 25, 2024 | marketwatch.comCassava shares sink on plans to stop Alzheimer's drug studiesNovember 25, 2024 | msn.comCassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goalsNovember 25, 2024 | msn.comCassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage StudiesNovember 25, 2024 | benzinga.comCassava Stock Plunges as Alzheimer's Drug Fails Late-Stage StudyNovember 25, 2024 | investopedia.comCassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goalsNovember 25, 2024 | marketwatch.comCassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market SessionNovember 25, 2024 | benzinga.comCassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary EndpointsNovember 25, 2024 | globenewswire.comCassava Sciences to Hold Corporate Update on November 25thNovember 24, 2024 | globenewswire.comCassava Sciences (NASDAQ:SAVA) Shares Gap Down - Time to Sell?Cassava Sciences (NASDAQ:SAVA) Shares Gap Down - Time to Sell?November 22, 2024 | marketbeat.comCassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nearsNovember 18, 2024 | msn.comCassava Sciences Appoints Freda Nassif as Chief Commercial OfficerNovember 18, 2024 | globenewswire.com Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking. Click here and I’ll show you exactly how to position your money SAVA Media Mentions By Week SAVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAVA News Sentiment▼0.130.75▲Average Medical News Sentiment SAVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAVA Articles This Week▼226▲SAVA Articles Average Week Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AnaptysBio News Today CorMedix News Today Xeris Biopharma News Today Cartesian Therapeutics News Today ABIVAX Société Anonyme News Today MeiraGTx News Today Monte Rosa Therapeutics News Today Esperion Therapeutics News Today ChromaDex News Today Alpha Teknova News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAVA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
